Kane Biotech was preparing the annual financial statements and, as part of the year-end procedures, assessed the assets and prepared the following alphabetized schedule based on adjusted values at December 31, 2023: (Do not round intermediate calculations. Round final answers to nearest whole dollar.) Asset Date of Purchase Deprec. Method* Cost Residual Value Useful Life Accum. Deprec. Recoverable Amount Equipment May 1/18 Units $ 49,000 $ 2,390 7,900 units $ 28,910 $ 5,390 Furniture Jun. 28/18 DDB 21,000 2,900 8 yrs 17,339 3,850 Land Apr. 5/18 N/A 94,000 N/A N/A N/A 110,800 Office building Apr. 5/18 SL 95,000 25,100 15 yrs 31,100 61,500 Warehouse Apr. 5/18 SL 68,500 19,000 20 yrs 21,938 54,100 *DDB = Double-declining-balance; SL = Straight-line; Units = Units-of-production; N/A = Not applicable Required: 1. Record any impairment losses at December 31, 2023. Assume Kane Biotech has recorded no impairment losses in previous years